BCG treatment for bladder cancer

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

研究此手术的领域

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 查找姓氏以该字母开头的医生 A
  2. 查找姓氏以该字母开头的医生 B
  3. 查找姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 查找姓氏以该字母开头的医生 F
  7. 查找姓氏以该字母开头的医生 G
  8. 查找姓氏以该字母开头的医生 H
  9. 查找姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 未找到姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 未找到姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 未找到姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 查找姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Jack R. Andrews, M.D.

    Jack R. Andrews, M.D.

    1. Urologist
    2. Oncologist
    1. Phoenix, AZ
    擅长领域：

    Nephrectomy, PSMA therapy, Lymphadenectomy, Transperineal prostate biopsy, Robotic prostatectomy, Radical prostatectomy..., Salvage therapy, BCG treatment for bladder cancer, Prostate cancer, Bladder cancer, Kidney cancer, Metastatic prostate cancer, Metastatic castration-resistant prostate cancer, Recurrent cancer, Penile cancer, Recurrent bladder cancer

  2. Paul E. Andrews, M.D.

    Paul E. Andrews, M.D.

    1. Urologist
    1. Phoenix, AZ
    擅长领域：

    Nephrectomy, Laparoscopic surgery, Robotic prostatectomy, Robotic surgery, Radical prostatectomy, Donor nephrectomy, BC...G treatment for bladder cancer, Prostate cancer, Bladder cancer, Kidney cancer, Testicular cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

  3. Stephen A. Boorjian, M.D.

    Stephen A. Boorjian, M.D.

    1. Urologist
    1. Rochester, MN
    擅长领域：

    Neobladder reconstruction, Nephrectomy, Robotic prostatectomy, Prostatectomy, Bladder cancer surgery, BCG treatment for... bladder cancer, Prostate cancer, Bladder cancer, Kidney cancer, Testicular cancer, Metastatic bladder cancer, Recurrent bladder cancer, Non-muscle invasive bladder cancer

  4. Ruqin Chen, M.D., M.B.

    Ruqin Chen, M.D., M.B.

    1. Oncologist
    1. Jacksonville, FL
    擅长领域：

    Chemotherapy, Immunotherapy, Targeted drug therapy, Hormone therapy for prostate cancer, Chemotherapy for prostate canc...er, BCG treatment for bladder cancer, Prostate cancer, Bladder cancer, Kidney cancer, Melanoma, Metastatic bladder cancer, Recurrent bladder cancer

  5. Scott M. Cheney, M.D.

    Scott M. Cheney, M.D.

    1. Phoenix, AZ
    擅长领域：

    Nephrectomy, Partial nephrectomy, HoLEP, Laparoscopic surgery, Ureteroscopy, Robotic surgery, Prostatectomy, Bladder ca...ncer surgery, BCG treatment for bladder cancer, Benign prostatic hyperplasia, Prostate cancer, Bladder cancer, Kidney cancer, Kidney stone, Prostate disorder, Ureteropelvic junction obstruction, Non-muscle invasive bladder cancer

  6. Dan S. Childs, M.D.

    Dan S. Childs, M.D.

    1. Oncologist
    1. Rochester, MN
    擅长领域：

    Cancer treatment, PSMA therapy, Cancer survivorship program, BCG treatment for bladder cancer, Cancer, Prostate cancer,... Bladder cancer, Kidney cancer, Testicular cancer, Rare disorders

  7. Meghan A. Cooper, D.O.

    Meghan A. Cooper, D.O.

    1. Urologist
    1. Rochester, MN
    擅长领域：

    Sacral nerve stimulation, Cystoscopy, Botox injection, Ureteroscopy, Laser PVP, Aquablation, Midurethral sling surgery,... Urethral bulking, Ureteral stent exchange, Ureteral stenting, Water vapor thermal therapy, Bladder biopsy, TURBT, BCG treatment for bladder cancer, Benign prostatic hyperplasia, Bladder cancer, Urinary incontinence, Overactive bladder, Kidney stone, Stress incontinence, Bladder outlet obstruction, Urge incontinence , Urinary retention, Urinary obstruction, Bladder stones, Scrotal masses, Non-muscle invasive bladder cancer

  8. Igor Frank, M.D.

    Igor Frank, M.D.

    1. Urologist
    1. Rochester, MN
    擅长领域：

    Robotic prostatectomy, Prostatectomy, BCG treatment for bladder cancer, Prostate cancer, Bladder cancer, Recurrent blad...der cancer, Non-muscle invasive bladder cancer

  9. Daniel M. Frendl, M.D., Ph.D.

    Daniel M. Frendl, M.D., Ph.D.

    1. Urologist
    1. Phoenix, AZ
    擅长领域：

    Cystoscopy, Rectal hydrogel spacer placement, Transurethral resection of the prostate, Ureteroscopy, Orchiectomy, Prost...ate biopsy, Ultrasound-guided surgery, MRI-guided biopsy, High-intensity focused ultrasound, Bladder biopsy, Prostate ablation, Irreversible electroporation, Prostate ultrasound, Ultrasound-guided prostate biopsy, BCG treatment for bladder cancer, Benign prostatic hyperplasia, Prostate cancer, Bladder cancer, Kidney stone

  10. Julio C. Gundian, Jr., M.D.

    Julio C. Gundian, Jr., M.D.

    1. Urologist
    1. Jacksonville, FL
    擅长领域：

    Cystoscopy, Vasectomy, Minimally invasive surgery, Prostate biopsy, BCG treatment for bladder cancer, Benign prostatic ...hyperplasia, Prostate cancer, Kidney tumor, Bladder cancer, Blood in urine, Kidney cyst, Recurrent bladder cancer

研究

Mayo Clinic researchers are advancing the understanding and treatment of bladder cancer through extensive investigation of BCG, examining how patients respond to this type of immunotherapy. They are exploring new therapeutic approaches for both BCG-naive disease and BCG-unresponsive disease, addressing critical unmet needs for patients whose cancers recur or progress despite standard therapy. These research efforts aim to personalize treatment, expand therapeutic options and improve quality of life for patients with bladder cancer through translational research and clinical innovation. Cancer research is conducted in coordination with Mayo Clinic Comprehensive Cancer Center.

Publications

See a list of publications about BCG treatment for bladder cancer by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Research Profiles

来自妙佑医疗国际员工
申请预约
关于
Sept. 18, 2026
打印
  1. Holzbeierlein JM, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. Journal of Urology. 2024; doi:10.1097/JU.0000000000003846.
  2. Flaig TW, et al. Bladder cancer, version 1.2026, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0022.
  3. Abou Chakra M, et al. Update on the mechanism of action of intravesical BCG therapy to treat non-muscle-invasive bladder cancer. Frontiers in Bioscience-Landmark. 2024; doi:10.31083/j.fbl2908295.
  4. Liatsos GD, et al. Review of BCG immunotherapy for bladder cancer. Clinical Microbiology Reviews. 2025; doi:10.1128/cmr.00194-23.
  5. TICE BCG (prescribing information). Merck Sharp & Dohme LLC; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a. Accessed Sept. 9, 2026.
  6. Oh C, et al. BCG intolerance in nonmuscle invasive bladder cancer — A systematic review. ANZ Journal of Surgery. 2025; doi:10.1111/ans.70281.
  7. Peng Y, et al. Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer. Human Vaccines & Immunotherapeutics. 2024; doi:10.1080/21645515.2024.2425529.
  8. Li R, et al. Bladder-sparing therapy for Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection. European Urology. 2024; doi:10.1016/j.eururo.2024.08.001.
  9. Abou Chakra M, et al. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: Where do we stand now? Expert Opinion on Pharmacotherapy. 2024; doi:10.1080/14656566.2024.2310073.
  10. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer. Accessed Sept. 9, 2026.
  11. Heiss BL, et al. FDA approval summary: Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ. Clinical Cancer Research. 2025; doi:10.1158/1078-0432.CCR-25-1231.
  12. Inlexzo (prescribing information). Janssen Biotech, Inc.; 2025. https://www.inlexzo.com. Accessed Sept. 9, 2026.
  13. Daneshmand S, et al. TAR-200 for Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: Results from the phase IIb SunRISe-1 study. Journal of Clinical Oncology. 2025; doi:10.1200/JCO-25-01651.
  14. Imfinzi (prescribing information). AstraZeneca Pharmaceuticals LP; 2026. https://www.imfinzi.com. Accessed Sept. 9, 2026.
  15. De Santis M, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): Final analysis of a randomised, open-label, phase 3 trial. The Lancet. 2025; doi:10.1016/S0140-6736(25)01897-5.
  16. Scilipoti P, et al. Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve high-risk non-muscle-invasive bladder cancer: Synthesis of evidence from the ALBAN, CREST, and POTOMAC trials. European Urology. 2026; doi:10.1016/j.eururo.2025.12.022.
  17. Medical review (expert opinion). Mayo Clinic. Sept. 15, 2026.

相关

BCG treatment for bladder cancer